TY - JOUR
AU - Rogier, Eric
AU - McCaffery, Jessica
AU - Nace, Doug
AU - Svigel, Samaly Souza
AU - Assefa, Ashenafi
AU - Hwang, Jimee
AU - Kariuki, Simon
AU - Samuels, Aaron
AU - Westercamp, Nelli
AU - Ratsimbasoa, Arsène
AU - Randrianarivelojosia, Milijaona
AU - Uwimana, Aline
AU - Udhayakumar, Venkatachalam
AU - Halsey, Eric
T1 - Plasmodium falciparum pfhrp2 and pfhrp3 Gene Deletions from Persons with Symptomatic Malaria Infection in Ethiopia, Kenya, Madagascar, and Rwanda
T2 - Emerging Infectious Disease journal
PY - 2022
VL - 28
IS - 3
SP - 608
SN - 1080-6059
AB -
Histidine-rich protein 2 (HRP2)–based rapid diagnostic tests detect Plasmodium falciparum malaria and are used throughout sub-Saharan Africa. However, deletions in the pfhrp2 and related pfhrp3 (pfhrp2/3) genes threaten use of these tests. Therapeutic efficacy studies (TESs) enroll persons with symptomatic P. falciparum infection. We screened TES samples collected during 2016–2018 in Ethiopia, Kenya, Rwanda, and Madagascar for HRP2/3, pan-Plasmodium lactate dehydrogenase, and pan-Plasmodium aldolase antigen levels and selected samples with low levels of HRP2/3 for pfhrp2/3 genotyping. We observed deletion of pfhrp3 in samples from all countries except Kenya. Single-gene deletions in pfhrp2 were observed in 1.4% (95% CI 0.2%–4.8%) of Ethiopia samples and in 0.6% (95% CI 0.2%–1.6%) of Madagascar samples, and dual pfhrp2/3 deletions were noted in 2.0% (95% CI 0.4%–5.9%) of Ethiopia samples. Although this study was not powered for precise prevalence estimates, evaluating TES samples revealed a low prevalence of pfhrp2/3 deletions in most sites.
KW - malaria
KW - sub-Saharan Africa
KW - Plasmodium falciparum
KW - pfhrp2
KW - pfhrp3
KW - gene deletion
KW - rapid diagnostic tests
KW - vector-borne infections
KW - therapeutic efficacy studies
KW - histidine-rich protein 2
KW - Ethiopia
KW - Kenya
KW - Madagascar
KW - Rwanda
DO - 10.3201/eid2803.211499
UR - https://wwwnc.cdc.gov/eid/article/28/3/21-1499_article
ER - End of Reference